NASDAQ
15.12.25 | 21:56
1,135 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 01.12. | TELA Bio stock price target lowered to $3 by Lake Street on sales issues | 1 | Investing.com | ||
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 17.11. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.11. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings | 1 | Benzinga.com | ||
| 14.11. | Piper Sandler lowers TELA Bio stock price target to $1.25 on soft Q3 results | 1 | Investing.com | ||
| 14.11. | TELA Bio stock price target lowered to $5 at Citizens on lower ASP | 1 | Investing.com | ||
| 14.11. | Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet | 1 | Seeking Alpha | ||
| 13.11. | Earnings call transcript: Tela Bio Q3 2025 sees revenue growth but EPS miss | 1 | Investing.com Deutsch | ||
| 13.11. | TELA Bio prices $13 million offering of common stock and warrants | 1 | Investing.com | ||
| 13.11. | TELA Bio prices $13M registered direct offering of common stock, pre-funded warrants | 2 | Seeking Alpha | ||
| 13.11. | TELA Bio, Inc.: TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants | 3 | GlobeNewswire (USA) | ||
| 13.11. | TELA Bio meldet 9 % Umsatzwachstum im 3. Quartal und passt Prognose für 2025 an | 1 | Investing.com Deutsch | ||
| 13.11. | TELA Bio GAAP EPS of -$0.19 beats by $0.02, revenue of $20.7M misses by $1.08M | 6 | Seeking Alpha | ||
| 13.11. | TELA Bio, Inc.: TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility | 87 | GlobeNewswire (Europe) | MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 04.11. | TELA Bio, Inc.: TELA Bio to Announce Third Quarter 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 03.11. | TELA Bio beruft William Plovanic in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 03.11. | TELA Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.10. | TELA Bio appoints healthcare leader Betty Jo Rocchio to board | 1 | Investing.com | ||
| 09.10. | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 25,400 | +1,15 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,275 | -0,38 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,46 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| MYRIAD GENETICS | 5,900 | -4,06 % | Myriad Genetics, Inc.: Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health | BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,090 | -2,68 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,554 | -0,56 % | CytomX-Aktie nach +1.000% - was jetzt? | Unser Community-Dauerbrenner CytomX Therapeutics hat sich seit unserem letzten Update Anfang Oktober weiter hervorragend entwickelt, konnte sich innerhalb eines Jahres mittlerweile verzehnfachen. Ist... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,705 | +0,22 % | Vir Biotechnology, Inc.: Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference | Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday... ► Artikel lesen | |
| RAPT THERAPEUTICS | 32,200 | +1,90 % | RAPT Therapeutics, Inc.: RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm plc - 15-12G, Securities registration termination | ||
| IMMUNOME | 22,440 | +14,37 % | Immunome's desmoid tumor treatment triumphs in phase 3, setting up approval filing | ||
| QIAGEN | 38,335 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| VERA THERAPEUTICS | 49,190 | -1,19 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,380 | +94,51 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| RADIOPHARM THERANOSTICS | 10,800 | +166,67 % | Radiopharm (RADX) Sees Slight Pessimism From Analysts | ||
| KYVERNA THERAPEUTICS | 10,880 | +23,92 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.